

**ASX/Media Release**

**12 September 2018**

## **Botanix BTX 1503 Clinical Trial Update**

- **BTX 1503 Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019**
- **Positive patient testimony from one of the first patients enrolled in the BTX 1503 acne Phase 2 clinical trial**

**Philadelphia PA and Sydney Australia, 12 September 2018:** Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”), is pleased to advise that following the recent commencement of the BTX 1503 acne Phase 2 clinical trial, one of the first patients enrolled into the clinical trial has demonstrated promising early results and provided a positive testimony.

BTX 1503, has been featured on 7News in which the feature highlights a positive patient testimony from one of the first patients enrolled in the BTX 1503 acne Phase 2 clinical trial. The 7News feature will be available on the Company’s website at [www.botanixpharma.com/investors](http://www.botanixpharma.com/investors).

The fully funded BTX 1503 acne Phase 2 clinical trial commenced in mid-CY2018 3Q and is expected to take approximately 12 months to complete. The clinical trial will evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne and is designed to deliver data that allows licensing and other corporate opportunities.

The BTX 1503 acne Phase 2 clinical trial is underway across the US and Australia, and currently has 10 sites actively recruiting in Australia. Additional information on phase 2 trials can be found following the link at: <https://newacnetrial.com/>

### **About Botanix Pharmaceuticals**

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4-12 week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. A further Phase 1b BTX 1308 psoriasis patient study is also scheduled to commence in 3Q CY2018.

For more information on Botanix, please visit [www.botanixpharma.com](http://www.botanixpharma.com)

**For more information, please contact:**

**General enquiries**

Matt Callahan  
Botanix Pharmaceuticals  
Founder & Executive Director  
+1 215 767 4184  
[mcallahan@botanixpharma.com](mailto:mcallahan@botanixpharma.com)

**Investor enquiries**

Joel Seah  
Vesparum Capital  
P: +61 3 8582 4800  
[botanixpharma@vesparum.com](mailto:botanixpharma@vesparum.com)

**Media enquiries**

Julia Maguire  
The Capital Network  
P: +61 419 815 386  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)